Vancouver, British Columbia Best Intestinal Disease Advocate
Vancouver, British Columbia Best Intestinal Disease Advocate (weneedideas.ca — April 9, 2013 ) Vancouver, British Columbia, Canada — – Has Recently Been Officially Named Vancouver, British Columbia’s “Best Intestinal Disease Advocate” on the internet Rob Hill and Intestinal Disease Education Awareness Society (IDEAS) Has Recently Been Officially Named Vancouver, British Columbia, Canada’s “Best Intestinal Disease [...]
Intestinal Disease Education and Awareness Society launches a new website
British Columbia, CA (IDEAS) June 18, 2012 Intestinal Disease Education and Awareness Society — We are pleased to announce an entirely new web site from IDEAS weneedideas.ca designed and built from the ground up with improved navigation, overall functionality, and for quick viewing, a mobile version. The web site will continue to provide Crohns, Ulcerative [...]
Phase 3 Study Results Show Anti-TNF SIMPONI® Active Ulcerative Colitis
Phase 3 Study Results Show Anti-TNF SIMPONI® Induced Clinical Response in Adults With Moderately to Severely Active Ulcerative Colitis First Presentation of Phase 3 Data Shows Significant Improvements in Clinical Remission, Mucosal Healing and Quality of Life Measures after SIMPONI Induction Treatment New study findings show that subcutaneous induction regimens of the anti-tumor necrosis [...]
Support IDEAS by shopping for Plants at Phoenix Perennials
Phoenix Perennials presents A Charity Shopping Weekend to Benefit Intestinal Disease Education and Awareness Society IDEAS May 12th and 13th 2012 10am-5pm Shop for plants and help fundraiser for a local charity! Who is IDEAS?: IDEAS raises awareness of intestinal diseases through education and public awareness campaigns. IDEAS provides quality of life enhancing programs for children and [...]
Humira Approved To Treat Ulcerative Colitis In Europe
Abbott’s HUMIRA® (adalimumab) Approved in Europe Treatment of Ulcerative Colitis (UC) HUMIRA® Becomes First and Only Self-injectable Biologic Therapy for the Treatment of Moderately to Severely Active UC in Adults April 11, 2012 Abbott Park, Illinois (NYSE: ABT) — Abbott today announced that the European Commission has approved HUMIRA® (adalimumab) for the treatment of moderately [...]
Abbott’s HUMIRA® (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study
Abbott’s HUMIRA® (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study May 10, 2011 Abbott Park, Illinois (NYSE: ABT) — Abbott’s HUMIRA® (adalimumab) met its primary endpoint of clinical remission in a Phase III study of adult patients with moderate to severe ulcerative colitis. Results were presented at the Digestive Disease Week (DDW) scientific [...]
Free Commission Review: